Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome
Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome
复制标题
DOI：
10.1016/j.metabol.2006.09.006
复制
发表时间：
2007-01-01
影响因子：
9.8
通讯作者：
Panidis, Dimitrios
中科院分区：
文献类型：
--
作者：
Diamanti-Kandarakis, Evanthia;Alexandraki, Krystallenia;Panidis, Dimitrios
多囊卵巢综合征（PCOS）患者的代谢和激素水平得到改善。其对心血管危险因素的治疗效果正在研究中。晚期糖基化终末产物（AGEs）是一种常见的致动脉粥样硬化分子，近年来发现PCOS患者血浆AGEs水平升高。本研究的目的是研究二甲双胍治疗对PCOS女性血浆AGE水平的影响。这是一项描述性临床试验。该研究涉及22名PCOS患者（年龄，25.09 ± 1.05岁;体重指数[BMI]，28.44 ± 1.51 kg/m2）和22名健康女性（年龄，26.50 ± 0.85岁; BMI，25.62 ± 1.30 kg/m2）。测量血浆AGE水平（U/mL），并确定所有受试者的代谢和激素概况。所有患有PCOS的女性每天接受1700 mg二甲双胍，持续6个月。22名PCOS患者接受二甲双胍治疗后AGEs水平降低（二甲双胍治疗前为9.98 +/- 0.13，二甲双胍治疗后为9.86 +/- 0.11，P = 0.05）。在一项亚组分析中，16名患有PCOS且葡萄糖耐量正常的女性中，AGE水平的下降得到加强（9.98 +/- 0.19 [之前] vs 9.81 +/- 0.15 [之后]，P = 0.02）。二甲双胍治疗后，除了睾酮水平（P = 0.01）和游离雄激素指数（P = 0.009）下降外，体重指数和其他研究参数保持不变。总之，二甲双胍治疗后，PCOS妇女血清中致动脉粥样硬化的AGE分子减少。这一发现在PCOS（2型糖尿病和心血管疾病的高危人群）中的临床相关性仍有待观察。未来的研究需要确认短期异常的治疗干预和预防这种综合征的长期后遗症的需要。(c)2007年爱思唯尔公司All rights reserved.
Metformin therapy in polycystic ovary syndrome (PCOS) improves metabolic and hormonal profiles. Its therapeutic effect on cardiovascular risk factors is under investigation. Advanced glycation end products (AGEs), well-known atherogenic molecules, were recently found to be elevated in plasma of women with PCOS. The purpose of the study was to investigate the effect of metformin treatment in plasma AGE levels of women with PCOS. This was a descriptive clinical trial. The study involved 22 patients with PCOS (age, 25.09 +/- 1.05 years; body mass index [BMI], 28.44 +/- 1.51 kg/m(2)) and 22 healthy women (age, 26.50 +/- 0.85 years; BMI, 25.62 +/- 1.30 kg/m(2)). Measurements of plasma AGE levels (U/mL) were performed, and the metabolic and hormonal profiles were determined in all subjects. All women with PCOS received a dose of 1700 mg metformin daily for 6 months. AGEs levels were reduced after metformin administration in 22 women with PCOS (9.98 +/- 0.13 [before metformin] vs 9.86 +/- 0.11 [after metformin], P =.05). In a subgroup analysis, of 16 women with PCOS and normal glucose tolerance, the drop of AGE levels was potentiated (9.98 +/- 0.19 [before] vs 9.81 +/- 0.15 [after], P =.02). Body mass index as well as the other parameters studied remained unchanged after metformin therapy apart from a drop of testosterone levels (P =.01) and free androgen index (P =.009). In conclusion, after metformin therapy, the atherogenic AGE molecules were reduced in the serum of women with PCOS. The clinical relevance of this finding in PCOS, a high-risk group for type 2 diabetes mellitus and cardiovascular disease, remains to be seen. Future studies are required to confirm the need of therapeutic intervention for short-term abnormalities and for prevention of long-term sequelae characterizing this syndrome. (c) 2007 Elsevier Inc. All rights reserved.